For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.

“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...

Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy ...

What naked mole-rats lack in the looks department they make up for it in longevity, living healthily for nearly four decades.

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug ...

By Stephen Beech Men with advanced prostate cancer have been offered fresh hope thanks to a "promising" new drug combination.

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical ...